XKH 001
Alternative Names: Anti-IL-25 monoclonal antibody - Kanova Biopharmaceutical; XKH-001Latest Information Update: 28 Jul 2025
At a glance
- Originator Kanova Biopharmaceutical
 - Class Anti-inflammatories; Antiallergics; Antiasthmatics; Monoclonal antibodies
 - Mechanism of Action Interleukin 17 inhibitors
 
- 
          
            
              Orphan Drug Status
              No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
 - New Molecular Entity Yes
 
Highest Development Phases
- Phase I/II Asthma
 - No development reported Hypersensitivity; Inflammation
 
Most Recent Events
- 28 Jul 2025 No recent reports of development identified for phase-I development in Allergy(In volunteers) in China (SC, Injection)
 - 28 Jul 2025 No recent reports of development identified for phase-I development in Inflammation(In volunteers) in China (SC, Injection)
 - 08 Jul 2025 Zhejiang Kanova Biopharmaceutical plans to initiate a phase II trial for Atopic Dermatitis in China (SC) (NCT07054736)